The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicians’ attitudes and preferences in choosing the first line drug for metastatic castration resistant prostate cancer (mCRPC): Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) in the clinical practice.
 
Orazio Caffo
Honoraria - Astellas Pharma; Janssen Oncology; Sanofi
 
Cinzia Ortega
Consulting or Advisory Role - Astellas Pharma
 
Teodoro Sava
No Relationships to Disclose
 
Cosimo Sacco
No Relationships to Disclose
 
Sandro Barni
No Relationships to Disclose
 
Paola Ermacora
No Relationships to Disclose
 
Francesca La Russa
No Relationships to Disclose
 
Francesca Maines
No Relationships to Disclose
 
Veronica Prati
No Relationships to Disclose
 
Fiorella Ruatta
No Relationships to Disclose
 
Antonello Veccia
No Relationships to Disclose
 
Enzo Galligioni
No Relationships to Disclose